<DOC>
	<DOC>NCT01763827</DOC>
	<brief_summary>The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.</brief_summary>
	<brief_title>Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male or female ≥ 18 to ≤ 80 years of age National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) Framingham risk score of 10% or less Fasting LDLC ≥ 100 mg/dL (2.6 mmol/L) and &lt;190 mg/dL Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) History of coronary heart disease New York Heart Association (NYHA) III or IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Diabetes mellitus (Type 1 diabetes, poorly controlled type 2 diabetes) Uncontrolled hypothyroidism or hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia</keyword>
</DOC>